Skip to content
Screener

AtriCure ATRC Q1 2026 earnings

Reported May 5, 2026 · After market close

Revenue$141.2MBeat by $1.5M
EPS$0.00Beat by $0.07
Revenue estimate$139.7M
EPS estimate-$0.07

Next report

Nov 4, 2026 (in 2 months)
Revenue estimate$151.2M
EPS estimate$0.01

Financials

Q1 2026

Income statement

See full
Revenue$141.2M+14.3%
Gross profit$109.3M+18.0%
Operating income$526.0K+109%
Net income$108.0K+102%
EPS (diluted)$0.00+100%

Balance sheet

See full
Cash & equivalents$146.2M+46.3%
Total debt$76.2M-3.1%
Total equity$491.7M+8.2%
Total assets$644.0M+8.8%

Cash flow

See full
Operating cash flow-$4.0M+63.8%
CapEx$3.9M+76.6%
Free cash flow-$7.8M+40.6%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$1.42B-9.9%
Enterprise value$1.35B-13.1%
P/S2.6×-0.7×

Profitability

See full
Gross margin75.6%+0.8pp
FCF margin9.7%—

Returns & leverage

See full
Debt / equity0.2×0.0×
Current ratio4.3×+0.2×

Segments

By geography

See full
Total International$25.0M+11.5%
Europe$16.1M+13.2%
Asia Pacific$7.1M—
Other International$1.9M+27.2%

By product

See full
Appendage management$60.0M+15.9%
Open ablation$48.6M+14.9%
Pain management$24.3M+27.8%
Minimally invasive ablation$8.3M-20.9%

FAQ

When did AtriCure report Q1 2026 earnings?
AtriCure (ATRC) reported Q1 2026 earnings on May 5, 2026 after market close.
What were AtriCure's Q1 2026 revenue and EPS?
AtriCure reported revenue of $141.2M and eps of $0.00 for Q1 2026.
Did AtriCure beat estimates in Q1 2026?
Revenue beat the consensus estimate of $139.7M by $1.5M. EPS beat the consensus estimate of $-0.07 by $0.07.
How did AtriCure's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 14.3% from $123.6M a year earlier.
Where can I find AtriCure's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001323885-26-000018) and the 10-Q periodic report (0001323885-26-000023) directly on SEC EDGAR. The filing index links above go to sec.gov.